Literature DB >> 24192218

Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.

M Ringelstein1, I Metz2, K Ruprecht3, A Koch4, J Rappold5, J Ingwersen1, C Mathys6, S Jarius7, W Brück2, H-P Hartung1, F Paul8, O Aktas9.   

Abstract

Longitudinally extensive transverse myelitis is characteristic but not pathognomonic for neuromyelitis optica spectrum disorders (NMOSDs) and may mimic local tumors. In this retrospective study based on a cohort of 175 NMOSD patients we identified seven patients who initially presented with a longitudinally extensive spinal cord lesion and underwent spinal cord biopsy due to magnetic resonance imaging (MRI)-suspected malignancies. Remarkably, routine neuropathology was inconclusive and did not guide the diagnostic process to anti-aquaporin-4 (AQP4)-seropositive NMOSD. Serious postoperative complications occurred in 5/7 patients and persisted during follow-up in 2/7 patients (29%). Considering these sequelae, AQP4-antibody testing should be mandatory in patients with inconclusive longitudinally extensive spinal cord lesions prior to biopsy.
© The Author(s) 2013.

Entities:  

Keywords:  Spinal cord tumor; aquaporin-4 antibody; longitudinally extensive spinal cord lesion; longitudinally extensive transverse myelitis; neuromyelitis optica; spinal biopsy

Mesh:

Substances:

Year:  2013        PMID: 24192218     DOI: 10.1177/1352458513510981

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].

Authors:  Orhan Aktas; Tania Kümpfel
Journal:  Nervenarzt       Date:  2021-03-16       Impact factor: 1.214

Review 2.  [Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].

Authors:  M Ringelstein; O Aktas; J Harmel; D Prayer; S Jarius; B Wildemann; H-P Hartung; S Salhofer-Polanyi; F Leutmezer; P S Rommer
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

3.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

4.  Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.

Authors:  Bogdan F G Popescu; Yong Guo; Mark E Jentoft; Joseph E Parisi; Vanda A Lennon; Sean J Pittock; Brian G Weinshenker; Dean M Wingerchuk; Caterina Giannini; Imke Metz; Wolfgang Brück; Elizabeth A Shuster; Jonathan Carter; Clara D Boyd; Stacey Lynn Clardy; Bruce A Cohen; Claudia F Lucchinetti
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

Review 5.  Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Authors:  Martin S Weber; Tobias Derfuss; Imke Metz; Wolfgang Brück
Journal:  Ther Adv Neurol Disord       Date:  2018-03-29       Impact factor: 6.570

Review 6.  [Differential diagnostics of autoimmune inflammatory spinal cord diseases].

Authors:  Frederike C Oertel; Michael Scheel; Claudia Chien; Antje Bischof; Carsten Finke; Friedemann Paul
Journal:  Nervenarzt       Date:  2021-03-25       Impact factor: 1.214

Review 7.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 8.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

9.  Neuromyelitis Optica Spectrum Disorder Associated with Cervical Spondylosis.

Authors:  Yuan Zhou; Lin Zhu; Hui-Lin Cheng; Yi-Xing Lin
Journal:  Chin Med J (Engl)       Date:  2015-11-20       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.